Precision Medicine

IntraBio's landmark FDA submission for levacetylleucine offers the first glimmer of an approved therapy for the devastating rare disease Ataxia-Telangiectasia.

An influential guidelines update expands options for a tough-to-treat bladder cancer, giving patients access to a novel gene therapy beyond its FDA label.

The University of Miami launches a new program to arm doctors with business skills, addressing a critical leadership gap in the evolving healthcare industry.

A new oral drug is being tested with existing therapies, offering a two-pronged attack on the glycogen buildup that defines this debilitating rare disease.

With pivotal trials advancing, key FDA alignment, and a strong cash position, Taysha Gene Therapies charts a clear path toward a potential breakthrough.

A novel blood test from C2N Diagnostics, used in a major Alzheimer's trial, shows promise in predicting disease progression, heralding a new era of precision medicine.

Endevica Bio launches Kalohexis, a new biotech aiming to disrupt the obesity market with a drug that resets the body's 'metabolic thermostat'.

With a new CFO who helped steer a multi-billion dollar acquisition, Bambusa Therapeutics signals major growth plans for its innovative antibody platform.

As its new obesity drug enters a key trial, Biohaven bets on a novel approach: reducing fat while preserving precious muscle mass. Can it redefine weight loss?

Belief BioMed's single-dose treatment for hemophilia B, BBM-H901, is now approved in Macao, offering a new horizon for patients beyond frequent injections.

A new DoD-funded trial combines a biologic drug with a plant-based supplement, aiming to break treatment barriers for ulcerative colitis, a major military issue.

With $2.1M in funding, Mave Health's new tDCS wearable claims to rewire your brain for focus and calm. But does the science support the hype?

With fresh funding secured, Dogwood Therapeutics pushes its promising nerve pain drug, Halneuron®, toward a pivotal data readout later this year.

How Robert Wood Johnson University Hospital eliminated a two-month backlog for sleep apnea testing, transforming patient care and offering a new healthcare model.

InflaRx announces a late-breaking presentation on its Phase 3 trial for vilobelimab, offering potential new hope for pyoderma gangrenosum patients.

SAB Biotherapeutics' public offering fuels late-stage trials for its promising T1D drug, SAB-142, aiming to change the treatment landscape.

With late-breaking hypertension data and an AI-driven platform, Kardigan is set to showcase a new, personalized approach to cardiovascular medicine.

The FDA grants PolyPid a crucial $4.3 million fee waiver for its D-PLEX₁₀₀ drug, freeing up vital cash to accelerate its commercial launch.

After regaining Nasdaq compliance, Incannex Healthcare is leveraging its $75M war chest to advance novel treatments for sleep apnea and anxiety.

A new collaboration will use Voro's 'masking' technology to create tumor-activated ADCs, aiming to make powerful cancer therapies safer and more effective.